Iovance Biotherapeutics Inc (NASDAQ:IOVA)

23.56
Delayed Data
As of 3:59pm ET
 -0.48 / -2.00%
Today’s Change
15.88
Today|||52-Week Range
54.21
-49.22%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.5B

Company Description

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Contact Information

Iovance Biotherapeutics, Inc.
999 Skyway Road
San Carlos California 94070
P:(650) 260-7120
Investor Relations:
16502607120264

Employees

Shareholders

Mutual fund holders52.98%
Other institutional50.32%
Individual stakeholders0.60%

Top Executives

Frederick G. VogtPresident, CEO, Secretary & General Counsel
Igor P. BilinskyChief Operating Officer
Jean-Marc BelleminCFO & Principal Accounting Officer
Friedrich Graf FinckensteinChief Medical Officer
Sara PellegrinoVP-Investor Relations & Public Relations